Accused of patent infringement again! Baolaite recently announced that the company has been sued for patent infringement by Shenzhen Mindray Biomedical Electronics Co., Ltd. (referred to as Mindray Medical or Mindray Company).

3 cases with a claim of 30 million yuan

On the evening of August 14th, Baolaite disclosed that the company had recently received legal documents such as subpoenas and "Civil Complaints" served by the Intermediate People's Court of Fuzhou City, Fujian Province, involving three patent dispute cases. In three cases, Mindray Medical claimed a total of 30 million yuan from Baolaite.

Specifically, the plaintiffs in the three cases are all Mindray Medical, while the first and second defendants are Baolaite and Nanping Chenrui Medical Equipment Co., Ltd. (hereinafter referred to as "Chenrui Company").

In Case 1, Mindray Medical believes that it and Shenzhen Mindray Technology Co., Ltd. are the patent holders of the invention with the patent number ZL201780051006.3 and the name "Medical Equipment". Baolaite manufactures, sells, and promises to sell the P1 model of monitors, while Chenrui Company sells the aforementioned models of monitors, which fall within the protection scope of Mindray Medical's patent rights. Baolaite and Chenrui Company shall bear legal liability for patent infringement.

The invention patents involved in Cases 2 and 3 are also related to the monitor. In both cases, Mindray Medical did not request economic compensation from Chenrui Company, but instead claimed 10 million yuan from Baolaite separately.

Mindray Medical is not the first to sue Baolaite

It is reported that this is not the first time that Mindray Medical has sued Baolaite. In April of this year, Baolaite disclosed that Mindray Medical has filed two patent infringement lawsuits against it, claiming a total of 10 million yuan.

Case 1:

In Case 1, Mindray Biotech believes that the P1 patient monitor manufactured, sold, and promised to be sold by Baolaite infringes on its design patent with patent number 201630419447.2 and the name "Monitor (N1)".

Therefore, Mindray Biotech requests the court to order the two defendants mentioned above to immediately cease their infringing behavior and claim 5 million yuan from Baolaite. From the announcement, it can be seen that Mindray Biological did not demand economic compensation from the defendant, Nanping Chenrui.

Case 2:

In Case 2, Mindray Bio sued that the patient monitor model P18 manufactured, sold, and promised to be sold by Baolaite infringed on its design patent number ZL201630126309.5 and the name "monitor".

Mindray Biotechnology requests the court to order Baolaite to immediately stop manufacturing, selling, and promising to sell the patient monitor model P18, destroy the finished and semi-finished products of the inventory product, destroy the advertisement and promotional printing materials of the product, delete the promotion and advertising of the product on the internet, and claim 5 million yuan; Defendant 2, Nanping Chenrui, immediately stopped selling patient monitors with model P18.

In two appearance patent litigation cases, Baolaite was claimed a total of 10 million yuan.

Baolaite: Focus on intellectual property construction and promote new product research and development

At the end of July 2023, Baolaite released its semi annual report for 2023. The report shows that as of June 30, 2023, the company and its subsidiaries have a total of 50 authorized invention patents, 272 utility models, 27 exterior designs, 1 international patent, 109 software copyrights, 108 trademarks, and 77 Medical Device Registration Certificates, ensuring that the company has a strong innovation and research and development advantage. During the reporting period, the company closely followed the research and development trends of domestic and foreign medical devices, combined with market demand and development strategy, and closely promoted the progress of research and development projects for new products such as G-series monitors, injection pumps, CRRT, AED, telemetry monitoring systems, infusion information collection systems, high-end dialysis water treatment equipment, and special formula hemodialysis concentrate

Baolaite stated that in the future, the company will further integrate cutting-edge technology for independent innovation, implement a strategy of high-end, differentiated, intelligent, IoT, and high-quality products, always guided by the needs of doctors and patients, and develop more new products with independent intellectual property rights, meet market future trends, and solve core pain points in the industry.

Pharmaceutical enterprises should attach importance to intellectual property rights

With the continuous deepening of market economy development, mastering independent intellectual property rights means possessing reliable core competitiveness, which can occupy a favorable position in the increasingly fierce market competition. The pharmaceutical industry, as a knowledge-based organization with outstanding professionalism, is a concentrated output of high-tech, and should pay more attention to the protection of intellectual property rights to achieve sustainable and healthy development of the pharmaceutical industry.

Not only that, pharmaceutical enterprises should also strengthen intellectual property management. Intellectual property management of pharmaceutical enterprises runs through the entire process of research and development and enterprise operation. From project screening, drug discovery, structural optimization to clinical development, drug registration, and market competition, intellectual property issues involved in various links need to be taken seriously. It is also necessary to establish a standardized system for the full lifecycle management of intellectual property rights within the enterprise, in order to safeguard the development and growth of the enterprise. As more and more pharmaceutical companies become bigger and stronger, the pharmaceutical industry will naturally become more prosperous and prosperous.

Note: The images and text are sourced from the internet. If you have any valuable suggestions, please feel free to contact us for updates and revisions!